Countries covered: Japan, France, Germany, Italy, Spain, United States
Around the world, the market success of branded drugs is influenced by changes in healthcare systems
and the growing role of payers - and at this point in time, economic concerns are prompting
waves of change, and payers are increasingly balking at healthcare costs and seeking ways to contain
expenditures. While the major-market healthcare authorities have cost-consciousness in common,
they are deploying various reforms and policies in different ways in pursuit of that goal. Understanding
international trends and market-specific measures will position biopharma players to operate
optimally in a host of distinct national environments.
Questions Answered in This Report
In November 2008, the U.S. presidential elections yielded a new Democratic administration and
Congress. What are the healthcare goals of the new administration? What progress has been
made thus far? What are the implications for the biopharmaceutical industry?
Also in November 2008, the U.K. Department of Health announced a series of key reforms. How
will drug prices be affected? What are the newest NICE-related adjustments?
Use of lower priced generics is a well-established cost-containment measure. How great is the
presence of generics in each major market? How are countries prompting increased use of
generics? When and how will generic versions of biologics (biosimilars) affect the sales of
branded pharmaceuticals?
In a cost-conscious environment, drug prices are under scrutiny. What are the key pricing trends
in the major markets? How are prices set and adjusted in each market? What strategies are
healthcare authorities and pharma companies using in their pricing negotiations?
Scope
Major markets: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Infrastructure: health system organization, funding sources, reform trends.
Drug pricing and reimbursement: price-setting policies, price control measures, prices
by major market, prices by drug type, outpatient drug pricing approaches, hospital drug approaches.
International trends: health technology assessment, generics and biosimilars, specialty
pharmaceuticals, flexible pricing arrangements, evidence of innovation.
(0 items)
